US protection ending in 2027: Chemically induced
As of the edition of 20 October 2026, 13 drugs have US protection that ends in 2027 in chemically induced; 7 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
13 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Anakinra | Ends 2027 (orphan exclusivity) | Marketed | Swedish Orphan Biovitrum | IL1R1 | 0 |
| Bevacizumab | Ends 2027 (orphan exclusivity) | Marketed | Roche | VEGFA | 2 |
| Desvenlafaxine | Ends 2027 (patent) | Marketed | Pfizer | SLC6A4 | 0 |
| Enzalutamide | Ends 2027 (patent) | Marketed | Astellas | AR | 1 |
| Fomepizole | Ends 2027 (patent) | Marketed | Endo | ADH1A, ADH1B, ADH1C | 3 |
| Lenalidomide | Ends 2027 (patent) | Marketed | Bristol Myers Squibb | CRBN | 0 |
| Mepolizumab | Ends 2027 (computed from the first US licence) | Marketed | GSK | IL5 | 0 |
| Pantoprazole | Ends 2027 (exclusivity) | Marketed | Pfizer | ATP4A | 1 |
| Rasagiline | Ends 2027 (patent) | Marketed | Teva | MAOB | 2 |
| Rifaximin | Ends 2027 (patent) | Marketed | Bausch Health | 0 | |
| Sacubitril | Ends 2027 (patent) | Marketed | Novartis | MME | 1 |
| Sebelipase alfa | Ends 2027 (computed from the first US licence) | Marketed | AstraZeneca | 0 | |
| Tapentadol | Ends 2027 (exclusivity) | Marketed | Collegium Pharmaceutical | OPRM1, SLC6A2 | 4 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2027 in chemically induced
In the product7 of these 13 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.